BeStock  
Stocks › Biotechnology › RXRX

Recursion Pharmaceuticals RXRX

US equityMarket cap rank #2863BiotechnologyAI medical concept stocks
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-3.7x
CheapRich

Above its usual level · 67th percentile, 5-year average -5.1x

Price / book2.2x
CheapRich

Below its usual level · 24th percentile, 5-year average 3.3x

#3251 of 5330 stocks by PB (1 = cheapest)

Price / sales29.1x
CheapRich

Near the bottom of its 5-year range · 13th percentile, 5-year average 61.2x

#4799 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-16x-11x-6x-1xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$6.80
Price vs. fair value-63.9%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.19 – 3.35 24% (cheaper than usual) #3251 of 5330 (1 = cheapest)
PE -3.70 -4.15 -5.11 67% (pricier than usual) –
PS 29.07 66.62 61.15 13% (cheaper than usual) #4799 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on RXRX.

Sign in to join the discussion.

Scroll to Top